Immunome
IMNM
19.10
-0.22
-1.11%
Immunome
US · IMNM
#2671 by market cap
Listed 2020
19.10
-0.22
-1.11%
Live - 5344 symbols - heartbeat 23s ago
· 2026-10-08 06:54
Pre-market
19.00
-0.50%
After-hours
19.10
0.00%
- Market cap
- 2.25B
- P/E (TTM)i
- -7.55
- P/Bi
- 4.29
- EPSi
- -2.43
- Div yieldi
- 0.00%
- 52W posi
- 34%
Reader sentiment
Are you bullish or bearish on IMNM?
Anonymous reader poll. Unscientific, not investment advice.
Analyst consensus 11 analysts
Buy
Avg price target
35.40 +85.4%
Price target rangecurrent 19.10
Low24.00
Avg35.40
High40.00
Buy 91%
Hold 9%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-10-05 | LifeSci Capital | -- | BUY | 40.00 |
| 2026-10-01 | Stifel | -- | HOLD | 24.00 |
| 2026-10-01 | Barclays | -- | BUY | 36.00 |
| 2026-09-30 | LifeSci Capital | -- | BUY | 40.00 |
| 2026-09-30 | Stifel | -- | HOLD | 24.00 |
| 2026-09-21 | A. G. P. | -- | BUY | 32.00 |
| 2026-09-11 | H.C. Wainwright | -- | BUY | 40.00 |
| 2026-09-10 | H.C. Wainwright | -- | BUY | 40.00 |
| 2026-08-12 | LifeSci Capital | -- | BUY | 40.00 |
| 2026-08-12 | Craig-Hallum | -- | BUY | 36.00 |
| 2026-08-12 | Piper Sandler | -- | BUY | 33.00 |
| 2026-08-12 | Truist Financial | -- | BUY | 38.00 |
| 2026-08-12 | Evercore | -- | BUY | 40.00 |
| 2026-08-12 | Guggenheim | -- | BUY | 35.00 |
| 2026-08-12 | H.C. Wainwright | -- | BUY | 40.00 |
| 2026-08-11 | TD Cowen | -- | BUY | -- |
| 2026-08-11 | Barclays | -- | BUY | 36.00 |
| 2026-07-20 | LifeSci Capital | -- | BUY | 40.00 |
| 2026-07-11 | LifeSci Capital | -- | BUY | 40.00 |
| 2026-07-09 | Truist Financial | -- | BUY | -- |
| 2026-07-09 | H.C. Wainwright | -- | BUY | 40.00 |
| 2026-07-09 | Barclays | -- | BUY | 36.00 |
| 2026-07-08 | LifeSci Capital | -- | BUY | 40.00 |
| 2026-06-29 | J.P. Morgan | -- | BUY | -- |
| 2026-06-12 | J.P. Morgan | -- | BUY | 39.00 |
Quant vs Street three independent views, side by side
Momentum strategy signal
Sell
Analyst consensus
Buy
Signals diverge - worth digging into why.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
Price target trend monthly average, last 3 years
Quote time 2026-10-08 06:54:41 · For reference only, not investment advice and not tailored to your situation.